輝瑞藥廠昨日宣佈，與德國BioNTech聯合研發的新冠疫苗，對12歲至15歲兒童保護效力可達100%。輝瑞將在數週內，向美國食品及藥物管理局（FDA）申請疫苗供兒童緊急使用。
輝瑞公開第三期兒童臨牀試驗數據顯示，2，260名參與試驗兒童中，完整接種與成人劑量相等的兩劑疫苗羣組無人受感染，安慰劑對照組則有18宗確診。兒童接種疫苗後，會出現與成人相似的發燒、疲倦和肌肉疼痛等副作用，打完第二針後副作用更明顯。
輝瑞上週還展開爲5歲至11歲兒童接種疫苗臨牀試驗，亦計劃下週起將6個月大以上嬰幼兒納入試驗範圍。以色列衞生部昨日表示，FDA批准後，以色列將爲12歲至15歲兒童接種輝瑞疫苗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments